Literature DB >> 19929727

The discovery of BMAA, and examples of biomagnification and protein incorporation involving other non-protein amino acids.

E Arthur Bell1.   

Abstract

Because of the similarity of ALS/PDC symptoms to those of the paralytic disease lathyrism, cycad seeds from Guam were analyzed for the presence of the non-protein amino acid b-ODAP, which is known to cause lathyrism. Although b-ODAP was not detected, a novel non-protein amino acid, now known as BMAA, was isolated. Primates are more sensitive to BMAA than rodents. It is possible that BMAA when ingested at a low concentration over a long period might be responsible for ALS/PDC. Some non-protein amino acids, including domoic acid and indospicine, are known to be biomagnified. Other non-protein amino acids including azetidine-2-carboxylic acid, canavanine, and selenium containing analogues of cystine and methionine have been shown to be misincorporated into proteins. Perhaps BMAA will not be the only non-protein amino acid that will be found in the brain tissues of those who died of a neurological disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19929727     DOI: 10.3109/17482960903268700

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  17 in total

1.  Assessment of the non-protein amino acid BMAA in Mediterranean mussel Mytilus galloprovincialis after feeding with estuarine cyanobacteria.

Authors:  Mafalda S Baptista; Rita G W Vasconcelos; Paula C Ferreira; C Marisa R Almeida; Vitor M Vasconcelos
Journal:  Environ Sci Pollut Res Int       Date:  2015-04-24       Impact factor: 4.223

2.  Roads, railways, and childhood cancers.

Authors:  E G Knox
Journal:  J Epidemiol Community Health       Date:  2006-02       Impact factor: 3.710

3.  Exposure to BMAA mirrors molecular processes linked to neurodegenerative disease.

Authors:  Joshua Beri; Tara Nash; Rubia M Martin; Michael S Bereman
Journal:  Proteomics       Date:  2017-08-24       Impact factor: 3.984

Review 4.  Methods for the Chemical Analysis of β-N-Methylamino-L-A lanine: What Is Known and What Remains to Be Determined.

Authors:  Sandra Anne Banack; Susan J Murch
Journal:  Neurotox Res       Date:  2017-05-04       Impact factor: 3.911

5.  Studies of Environmental Risk Factors in Amyotrophic Lateral Sclerosis (ALS) and a Phase I Clinical Trial of L-Serine.

Authors:  Walter G Bradley; R X Miller; T D Levine; E W Stommel; P A Cox
Journal:  Neurotox Res       Date:  2017-05-19       Impact factor: 3.911

Review 6.  BMAA and Neurodegenerative Illness.

Authors:  Paul Alan Cox; Richard M Kostrzewa; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2017-05-24       Impact factor: 3.911

7.  Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite.

Authors:  Marco Vinceti; Nikolay Solovyev; Jessica Mandrioli; Catherine M Crespi; Francesca Bonvicini; Elisa Arcolin; Eleni Georgoulopoulou; Bernhard Michalke
Journal:  Neurotoxicology       Date:  2013-05-31       Impact factor: 4.294

Review 8.  Exposure to environmental toxicants and pathogenesis of amyotrophic lateral sclerosis: state of the art and research perspectives.

Authors:  Francesca Trojsi; Maria Rosaria Monsurrò; Gioacchino Tedeschi
Journal:  Int J Mol Sci       Date:  2013-07-24       Impact factor: 5.923

9.  BMAA, Neurodegeneration, and Neuroprotection.

Authors:  Paul Alan Cox
Journal:  Neurotox Res       Date:  2020-11-16       Impact factor: 3.911

10.  A comparative study on three analytical methods for the determination of the neurotoxin BMAA in cyanobacteria.

Authors:  Elisabeth J Faassen; Frits Gillissen; Miquel Lürling
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.